Pulmonary-Allergy,Dermatological, Gastrointestinal & Arthritis: β-Lactams as inhibitors of human leukocyte elastase

This series of patents from Merck discloses novel β-lactams (azetidinones) as inhibitors of human leukocyte elastase (HLE).     

5-Benzamidoisoquinolin-1-ones and 5-(ω-carboxyalkyl)isoquinolin-1-ones as isoform-selective inhibitors of poly(ADP-ribose) polymerase 2 (PARP-2)

PARP-2 is a member of the poly(ADP-ribose) polymerase family, with some activities similar to those of PARP-1 but with other distinct roles. Two series of isoquinolin-1-ones were designed, synthesized, and evaluated as selective inhibitors of PARP-2, using the structures of the catalytic sites of the isoforms. A new efficient synthesis of 5-aminoisoquinolin-1-one was developed, and acylation with acyl chlorides gave 5-acylaminoisoquinolin-1-ones. By examination of isoquinolin-1-ones with carboxylates tethered to the 5-position, Heck coupling of 5-iodoisoquinolin-1-one furnished the 5-CH═CHCO(2)H compound for reduction to the 5-propanoic acid. Alkylation of 5-aminoisoquinolin-1-one under mildly basic conditions, followed by hydrolysis, gave 5-(carboxymethylamino)isoquinolin-1-one, whereas it was alkylated at 2-N with methyl propenoate and strong base. Compounds were assayed in vitro for inhibition of PARP-1 and PARP-2, using FlashPlate and solution-phase assays, respectively. The 5-benzamidoisoquinolin-1-ones were more selective for inhibition of PARP-2, whereas the 5-(ω-carboxyalkyl)isoquinolin-1-ones were less so. 5-Benzamidoisoquinolin-1-one is the most PARP-2-selective compound (IC(50(PARP-1))/IC(50(PARP-2)) = 9.3) to date, in a comparative study.     

Synthesis of 6-[1-[4-(benzoxazol-2-yl)thiobuthyl]-1,2,3-triazole-4-yl]methylenepenam as β-lactamase inhibitors

The 6,6-dibromopenam6 was treated with CH₃MgBr and carbaldehyde5 to afford the 6-bromo-6-(1-hydroxy-1-methyl)penicillanate7, which was reacted with acetic anhydride to give acetoxy compound8. The deacetobromination of8 with zinc and acetic acid gave 6-exomethylenpenams, Z-isomer9 and E-isomer10, which were oxidized to sulfones11 and12 by m-CPBA. The p-methoxybenzyl compounds were deprotected by AlCl₃ and neutralized to give the sodium salts13, 14, and15.     

Zeolite-catalyzed synthesis of quinazolin-4(3H)-ones through selective cleavage of C–C bond of 1,3-diketones under solvent-free conditions

A wide range of quinazolin-4(3H)-ones have been synthesized from readily accessible precursors such as anthranilamide and 1,3-diketones. This reaction was promoted by the heterogeneous beta zeolite as the catalyst via a selective cleavage of the C–C bond of 1,3-diketones. This reaction went smoothly with various 1,3-diketones (cyclic and acyclic) affording 2-aryl and 2-alkyl substituted quinazolin-4(3H)-ones in good to excellent yields. The notable point of this strategy is that it can avoid the involvement of toxic transition metals, additives and corrosive oxidants establishing this method as green and feasible. Besides, this method displays its capacity for gram-scale reactions (up to 10 g). Moreover, in this process the recyclability of the recovered catalyst without drastic changes until 5 cycles have been presented.     

Synthesis and biochemical evaluation of δ(2)-isoxazoline derivatives as DNA methyltransferase 1 inhibitors

A series of Δ(2)-isoxazoline constrained analogues of procaine/procainamide (7a-k and 8a-k) were prepared and their inhibitory activity against DNA methyltransferase 1 (DNMT1) was tested. Among them, derivative 7b is far more potent in vitro (IC(50) = 150 μM) than other non-nucleoside inhibitors and also exhibits a strong and dose-dependent antiproliferative effect against HCT116 human colon carcinoma cells. The binding mode of 7b with the enzyme was also investigated by means of a simple competition assay as well as of docking simulations conducted using the recently published crystallographic structure of human DNMT1. On the basis of the findings, we assessed that the mode of inhibition of 7b is consistent with a competition with the cofactor and propose it as a novel lead compound for the development of non-nucleoside DNMT inhibitors.     

Synthesis of 5-chloro-3-[4-(3-diethylaminopropoxy)benzoyl]-2-(4-methoxyphenyl)benzofuran as a β-amyloid aggregation Inhibitor

An efficient synthesis of 5-chloro-3-[4-(3-diethylaminopropoxy)benzoyl]-2-(4-methoxyphenyl)benzofuran (8), a potent beta-amyloid aggregation inhibitor, is described. 5-Chloro-2-(4-methoxyphenyl)benzofuran (3) was obtained by the one-pot synthesis of 4-chlorophenol with omega-(methylsulfinyl)-p-methoxyacetophenone (1) under Pummerer reaction conditions, and it was followed by the desulfurization of the resultant 5-chloro-3-methylthio-2-(4-methoxyphenyl)benzofuran (2e). Acylation of benzofuran 3 with 4-(3-bromopropoxy)benzoyl chloride (6) gave the ketone 7, which was converted into compound 8 by the treatment of diethylamine.     

Synthesis and antimicrobial activity of 2-alkyl-1-[2′-chloro(diethylamino,morpholino)methylcarbonylethoxy]pyrroles

A series of previously unreported 2-alkyl-1-(2-chloromethylcarbonylethoxy)pyrroles have been synthesized via reaction of 2-alkly-1-(2-hydroxyethyl)pyrroles with chloroacetyl chloride and reaction of the intermediates with secondary amines to give 2-alkyl-1-[2-diethylamino(morpholino)methylcarbonylethoxy]pyrroles. Their antimicrobial activity has been studied. It is established that electron-accepting substituents in the methylcarbonylethoxy chain increase whereas electron-donating ones decrease the antimicrobial activity of the pyrroles in the order chlorine > morpholine > diethylamine.     

三酮类除草剂2-(2-硝基-4-三氟甲基苄基)-环己烷-1,3-二酮(NTBC)毒理学研究进展

<正>三酮类是一种新型植物4-羟苯丙酮酸二加氧酶(4-Hydroxyphenylpyruvate dioxygenase,HPPD)抑制剂类选择性除草剂[1],因其杀草谱广、活性高、可混性强、对后茬作物安全,使用灵活、残留低、环境相容性好等特点,在世界各国获得广泛使用[2]。然而,三酮类除草剂也是哺乳动物体内HPPD有效抑制剂,因此作为一种植物和哺乳动物共有靶标位点的除草剂,其潜在的哺乳动物安全性问题不容忽视[3]。本文通过对     

新型免疫抑制剂2-氨基-2-[2-(4-正辛基苯基)乙基]-1,3-丙二醇盐酸盐(FTY720)的合成

目的 合成新型免疫抑制剂2-氨基- 2-[2-(4-正辛基苯基)乙基]-1,3-丙二醇盐酸盐(FTY720)。方法 以氯化苄和溴代正庚烷为起始原料,经Wurtz偶联、氯乙酰化、缩合、羰基还原、酯基还原、去乙酰化和成盐反应得到目的化合物FTY720,总收率为22.5％。结果与结论 目标化合物的结构经 1H-NMR、13C-NMR和MS确证。中间体的1H-NMR谱和熔点与文献值相符。该合成路线成本低廉,步骤较短,操作简单。     

2-氨基-2-[2-(4-正辛基苯基)乙基]-1,3-丙二醇盐酸盐的合成工艺改进

目的 合成新型免疫抑制剂2-氨基-2-[2-（4-正辛基苯基）乙基]-1，3-丙二醇盐酸盐（FTY-720）。方法 以苯和正辛酰氯为起始原料，经傅克酰基化、还原、酰化、缩合、还原羰基、还原酯基、去乙酰化和成盐反应得到目的化合物FTY-720，总收率为12．0％。结果与结论 目标化合物的结构经^1H-NMR、IR和MS确证，中间体的^1H-NMR谱和mp值与文献值相符。该合成路线成本低廉，操作简单。     

Atypical antipsychotics as noncompetitive inhibitors of α4β2 and α7 neuronal nicotinic receptors

It has been suggested that the interaction of antipsychotic medications with neuronal nicotinic receptors may increase the cognitive dysfunction associated with schizophrenia and may explain why current therapies only partially address this core feature of the illness. In the present studies we compared the effects of the atypical antipsychotics quetiapine, clozapine and N-desmethylclozapine to those of the typical antipsychotics haloperidol and chlorpromazine on the α4β2 and α7 nicotinic receptor subtypes. The binding of [³H]-nicotine to rat cortical α4β2 receptors and [³H]-methyllycaconitine to rat hippocampal α7 receptors was not affected by any of the compounds tested. However, Rb⁺ efflux evoked either by nicotine or the selective α4β2 agonist TC-1827 from α4β2 receptors expressed in SH-EP1 cells and nicotine-evoked [³H]-dopamine release from rat striatal synaptosomes were non-competitively inhibited by all of the antipsychotics. Similarly, α-bungarotoxin-sensitive epibatidine-evoked [³H]-norepinephrine release from rat hippocampal slices and acetylcholine-activated currents of α7 nicotinic receptors expressed in oocytes were inhibited by haloperidol, chlorpromazine, clozapine and N-desmethylclozapine. The inhibitory effects on nicotinic receptor function produced by the antipsychotics tested occurred at concentrations similar to plasma levels achieved in schizophrenia patients, suggesting that they may lead to clinically relevant effects on cognition.     

The psycho- and neurotropic profiling of novel 3-(N-R,R′-aminomethyl)-2-methyl-1H-quinolin-4-ones in vivo

The article presents the study of psycho- and neurotropic properties of novel 3-(N-R,R′-aminomethyl)-2-methyl-1H-quinolin-4-ones in vivo. The research was carried out using the open field test, elevated plus maze, rotarod test, tail suspension test, passive avoidance test after scopolamine-induced amnesia and acute normobaric hypoxia with hypercapnia. As a result, two promising substances have been found. According to our results 3-[[(4-methoxyphenyl)amino]methyl]-2-methyl-1H-quinolin-4-one in the dose of 10?mg/kg shows a specific sedative effect and a considerable anti-amnesic activity. The most interesting N-[(2-methyl-4-oxo-1H-quinolin-3-yl)methyl]-N-phenylbenzamide (100?mg/kg) combines a potent anti-anxiety action, the anti-amnesic activity and a considerable antihypoxic effect. They are of interest for further profound studies as promising psychoactive compounds.     

Synthesis of N-[3′-(acetylthio)alkanoyl] and N-[3′-mercaptoalkanoyl]-4-α(s)-(phenylmethyl) pyroglutamic acids and prolines as potent ACE inhibitors

Abstract  

Angiotensin converting enzyme (ACE) inhibitors have emerged as a revolution in antihypertensive therapy. Introduction of captopril, the first rationally designed ACE inhibitor, has encouraged researchers all over the world to design and synthesize target molecules controlling hypertension based on these lines. It has been observed that replacing proline part of captopril with 4-substituted prolines or 5-oxo-prolines led to significant enhancement in ACE inhibitory activity, and this observation prompted us to design and synthesize N-acyl 4-substituted pyroglutamates and prolinates with the objective of developing therapeutically better ACE inhibitors. Herein we describe an easy approach for N-acylation of 4-α(S)-(phenylmethyl) pyroglutamates with the aim of synthesizing N-[3′-(acetylthio)alkanoyl] and N-[3′-mercaptoalkanoyl]-4-α-(s)-(phenylmethyl) pyroglutamic acids and prolines as ACE inhibitors.     

Design, synthesis and pharmacological evaluation of 4-[2-alkylthio-5（4）-（4- substitutedphenyl）imidazole-4（5）yl]benzenesulfonamides as selective COX-2 inhibitors

Aim： To design and synthesize a series of benzenesulfonamide derivatives, 4-[2- alkylthio-5 （4）-（4-substitutedphenyl）imidazole-4（5）-yl]benzenesul fonamides （4a-4j）, which are intended to act as cyclooxygenase-2 （COX-2） inhibitors with good COX-2 inhibitor activity, and which will exert anti-inflammatory activities in vivo. Methods： Benzenesulfonamide derivatives were designed and synthesized through multi-step chemical reactions. All the synthesized compounds were evaluated in an in vitro assay. The active compound 4a-4f was selected for further evaluation in a carrageenan-induced rat paw edema model. Results： Docking studies showed that compound 4 bind into the primary binding site of COX-2 with the sulfonamide SO2NH2 moiety interacting with the secondary pocket amino acid residues. In the in vitro assay, compound 4 inhibited COX-2 with an inhibition concentration IC50 value of 1.23-8 nmol/L, compared to celecoxib with IC50 value of 1.5 nmol/L. Compound 4b and 4c had good potency and selectivity in comparison to the celecoxib. In the in vivo model, compound 4a-4f exhibited a moderate potency to inhibit 50% carrageenan-induced paw edema with value of 1.58-4.3 mg/kg. In the latter experiment, compound 4c was the most active compound. Conclusion： The antiinflammatory effects obtained for compound 4a-4j could be due to the presence of fluorine or hydrogen substituents in the para position of the phenyl ring of these compounds.     

Modulation of human α(4)β(2) nicotinic acetylcholine receptors by brominated and halogen-free flame retardants as a measure for in vitro neurotoxicity

Brominated flame retardants (BFRs) are abundant persistent organic pollutants with well-studied toxicity. The toxicological and ecological concern associated with BFRs argues for replacement by safer alternatives. However, the (neuro)toxic potential of alternative halogen-free flame retardants (HFFRs) is unknown. Previous research identified the nervous system as a sensitive target organ for BFRs, with modulation of excitatory nicotinic acetylcholine (nACh) receptors as one of the modes of action. Since it is essential to assess the (neuro)toxic potential of HFFRs before large scale use, we measured the effects of three BFRs and 13 HFFRs on the function of human α(4)β(2) nACh receptors, expressed in Xenopus oocytes, using the two-electrode voltage-clamp technique. The results demonstrate that some BFRs (TBBPA and to a lesser extent BDE-209) and HFFRs (TPP, Alpi, APP, MMT and to a lesser extent ATH, ATO, MHO, MPP, RDP and ZHS) act as nACh receptor antagonists. Contrary, BPS, BDP, DOPO and ZS were unable to modulate nACh receptors. Despite the lack of toxicological data on HFFRs and the need for additional studies to perform a full (neuro)toxic risk assessment, the current data on antagonistic effects on nACh receptors could be an important step in prioritizing viable HFFRs for substitution of BFRs.     

Synthesis and Pharmacokinetics of 2-(4-amino-3,5-dichlorophenyl)-2-(alkylamino)ethanols - Structural Isomers of β2 Agonists Clenproperol and Clenpenterol

Pharmaceutical Chemistry Journal - Methods for the synthesis of 2-(4-amino-3,5-dichlorophenyl)-2-(isopropylamino)ethanol and 2-(4-amino-3,5-dichlorophenyl)-2-(tert-amylamino)ethanol, which are...